The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic.
We undertook an analysis of the hazard functions derived from results published by the Parkinson Study Group following their investigation of deprenyl. Our findings indicate that the action of deprenyl is transient rather than sustained. We also infer that this effect may be mediated through alleviation of symptoms rather than by neuroprotection.
Schulzer
M
M
Department of Medicine, University Hospital, Vancouver, BC, Canada.
Mak
E
E
Calne
D B
DB
D006801:Humans; D015233:Models, Statistical; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D012642:Selegiline / Q000627:therapeutic use*; D016019:Survival Analysis
D012642:Selegiline